An update on NIH RECOVER-TLC treatment trials, including baricitinib, low-dose naltrexone, semaglutide, and stellate ganglion block.
CDC's guidance for clinicians on symptom-focused, patient-centered Long COVID treatment plans, with a dedicated section on managing PEM.
No completed RCTs of low-dose naltrexone exist yet, but small observational studies report moderate-to-large improvements in fatigue and brain fog.
Three trials are testing JAK inhibitor drugs for immune dysregulation believed to underlie some Long COVID symptoms, with mixed patient experiences so far.
Reports on the failure of a BC 007 infusion drug trial for Long COVID and what researchers are learning for future trial design.
A free clinical guide for providers covering diagnosis, symptom management, and multidisciplinary care for ME/CFS and Long COVID.
A placebo-controlled phase 2 trial of a 15-day Paxlovid course in adults with Long COVID found no significant improvement at day 28.
Reports on progress identifying possible mechanisms while noting no treatments are yet approved and fewer than 50 trials are active.
The first randomized, placebo-controlled Paxlovid trial for Long COVID found the drug safe but without statistically significant symptom improvement.
Explains PESE/PEM, its triggers, and why graded exercise therapy is not recommended for people with post-exertional symptom worsening.
A patient-led physiotherapist group's guide to pacing as a strategy for balancing activity and rest to avoid triggering post-exertional symptoms.
Describes Mayo Clinic's COVID-19 Activity Rehabilitation Program and reports on the characteristics of its first 100 patients.